| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PTH2R |
| Uniprot No | P49190 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-145aa |
| 氨基酸序列 | DSDGTITIEEQIVLVLKAKVQCELNITAQLQEGEGNCFPEWDGLICWPRGTVGKISAVPCPPYIYDFNHKGVAFRHCNPNGTWDFMHSLNKTWANYSDCLRFLQPDISIGKQEFFERLY |
| 预测分子量 | 29.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于PTH2R(Parathyroid Hormone 2 Receptor)重组蛋白的研究文献及其摘要概括：
---
1. **文献名称**：Structural mechanism of ligand activation in human PTH2 receptor
**作者**：Zhao et al.
**摘要**：本研究通过冷冻电镜技术解析了人源PTH2R受体与其天然配体TIP39结合的复合物结构，揭示了该受体激活的分子机制，并阐明了其与G蛋白偶联的构象变化，为开发靶向PTH2R的疾病治疗药物提供了结构基础。
---
2. **文献名称**：Expression and functional characterization of recombinant human PTH2 receptor in insect cells
**作者**：Hoare et al.
**摘要**：作者在昆虫细胞(Sf9)系统中成功表达并纯化了功能性人源PTH2R重组蛋白，通过放射性配体结合实验和cAMP信号检测验证了受体与配体TIP39的特异性结合及信号激活能力，为高通量筛选PTH2R调节剂奠定了基础。
---
3. **文献名称**：PTH2 receptor modulates osteoclast differentiation via cAMP/PKA signaling
**作者**：Bowler et al.
**摘要**：研究利用重组PTH2R蛋白体外模型，证明其激活后通过cAMP/PKA通路抑制破骨细胞分化，提示PTH2R在骨代谢中的潜在调控作用，为骨质疏松症治疗提供了新靶点。
---
4. **文献名称**：Differential activation of PTH1R and PTH2R by engineered ligand analogs
**作者**：Carter et al.
**摘要**：通过比较重组表达的PTH1R和PTH2R对不同合成配体的响应，发现两类受体在配体结合口袋的关键氨基酸差异导致信号选择性，为开发PTH2R特异性激动剂/拮抗剂提供了理论依据。
---
以上文献涵盖了PTH2R的结构解析、重组表达、信号机制及疾病关联研究，均为该领域的代表性工作。如需具体DOI或发表年份，可进一步补充检索。
**Background of PTH2R Recombinant Protein**
The parathyroid hormone 2 receptor (PTH2R) is a class B G protein-coupled receptor (GPCR) that plays a critical role in regulating calcium homeostasis, bone metabolism, and neuroendocrine functions. It is activated primarily by parathyroid hormone (PTH), a key hormone involved in calcium and phosphate balance, and tuberoinfundibular peptide of 39 residues (TIP39), a neuropeptide linked to stress responses and nociception. PTH2R is expressed in tissues such as the brain, kidneys, and bones, highlighting its diverse physiological roles.
Recombinant PTH2R protein is engineered through molecular cloning and heterologous expression systems (e.g., mammalian cells or insect cells) to produce purified, functional receptor proteins for research and therapeutic development. Its recombinant form enables detailed structural and functional studies, including ligand-binding assays, signal transduction analyses, and high-throughput drug screening. Researchers leverage this tool to investigate PTH2R’s activation mechanisms, downstream signaling pathways (e.g., cAMP/PKA), and interactions with ligands or modulators.
Interest in PTH2R stems from its potential as a therapeutic target for disorders like osteoporosis, hyperparathyroidism, and chronic pain. However, its physiological overlap with PTH1R (another PTH receptor subtype) and complex tissue-specific signaling pose challenges in drug design. Recent advances in cryo-EM and structural biology have shed light on PTH2R’s activation states, aiding the development of selective agonists or antagonists.
Overall, PTH2R recombinant protein serves as a vital resource for unraveling the receptor’s biology and accelerating targeted therapies for metabolic and neurological diseases.
×
